Synergistic anti-tumor effects of zoledronic acid and radiotherapy against metastatic hepatocellular carcinoma

Kazuhiko Morii, Yuhki Aoyama, Shinichiro Nakamura, Hiroaki Okushin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 72-year-old man with advanced hepatocellular carcinoma and decompensated hepatitis C virus-related cirrhosis suffered from a metastatic femoral fracture. After undergoing radiotherapy, he was only treated with supportive care, except for the administration of zoledronic acid (ZA). Thereafter, the initially elevated serum a-fetoprotein and des-gamma carboxyprothrombin levels declined to within the normal ranges. Hepatic and metastatic adrenal tumors, distant from the radiation field, exhibited a surprising regression. ZA is known to inhibit the activity of osteoclasts, bone-residential macrophages, and has been reported to have a direct antitumor effect. ZA may adjust the immunological milieu in tumor microenvironments by inhibiting the tumorassociated macrophages. Because radiotherapy can enhance the presentation of tumor-associated antigens, ZA and radiotherapy may exert synergistic anti-tumor effects.

Original languageEnglish
Pages (from-to)2609-2613
Number of pages5
JournalInternal Medicine
Volume54
Issue number20
DOIs
Publication statusPublished - Oct 15 2015

Keywords

  • Hepatocellular carcinoma
  • Radiotherapy
  • Tumor microenvironment
  • Tumor-associated macrophage
  • Zoledronic acid

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Synergistic anti-tumor effects of zoledronic acid and radiotherapy against metastatic hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this